Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage.
Two potential cleavage sites have been identified on precursor gp 160 of human immunodeficiency virus type 1. Using antibodies directed against the C-terminus of gp 120, including the sequence between the two sites, we have shown that nonmutated viral and recombinant gp 160 are cleaved at both sites: the great majority of molecules are cleaved at site 1 (Arg-Glu-Lys-Arg), and gp41 can then associate as an oligomer; a minority of molecules are cleaved at site 2 (Lys-Ala-Lys-Arg-Arg) and the corresponding gp41 appears to present as a monomer. This could reflect two different processing pathways for gp41 biosynthesis, one of which only may result in biologically active molecules according to the literature.
Laboratoire de Biologie et Génétique des Pathologies Immunitaires, CNRS URA 1463, CERVI, Hôpital de la Pitié-Salpêtrière, Paris, France.
E
E
Fenouillet
J C
JC
Gluckman
D000595:Amino Acid Sequence; D010450:Endopeptidases / Q000378:metabolism; D000939:Epitopes; D015686:Gene Products, env / Q000276:immunology / Q000378:metabolism*; D015699:HIV Envelope Protein gp120 / Q000276:immunology / Q000378:metabolism; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41 / Q000276:immunology / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology / Q000378:metabolism*; D008969:Molecular Sequence Data; D011498:Protein Precursors / Q000276:immunology / Q000378:metabolism*; D011499:Protein Processing, Post-Translational
D000939:Epitopes; D015686:Gene Products, env; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41; D011498:Protein Precursors; D010450:Endopeptidases